Research Output Journal of Engineering and Scientific Research 5(1): 21-28, 2026

ROJESR Publications Online ISSN: 1115-9790

https://rojournals.org/roj-engineering-and-scientific-research/ Print ISSN: 1115-6155

https://doi.org/10.59298/ROJESR/2026/5.12128

RTS, S/AS01 Malaria Vaccine Implementation in High-Transmission Sub-Saharan African Pediatric Populations: Efficacy and Challenges

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Malaria remains a leading cause of pediatric morbidity and mortality in sub-Saharan Africa, with *Plasmodium falciparum* accounting for over 90% of cases in high-transmission regions. The RTS, S/AS01 vaccine represents the first licensed malaria vaccine, targeting the circumsporozoite protein to prevent sporozoite invasion of hepatocytes. This review critically synthesizes evidence on RTS, S/AS01 implementation in high-transmission sub-Saharan African pediatric populations, focusing on molecular mechanisms, clinical efficacy, and programmatic challenges. A systematic literature search was conducted in PubMed, Embase, and Web of Science databases (2015–2024), selecting randomized controlled trials, implementation studies, immunological analyses, and systematic reviews. Phase III clinical trials demonstrated modest efficacy of 36% against clinical malaria and 32% against severe malaria in children aged 5–17 months following a four-dose regimen, with waning immunity requiring booster doses. Immunological studies reveal that RTS, S/AS01 induces anti-circumsporozoite antibodies and CD4+ T-cell responses, though protection is incomplete and variant-dependent. Pilot implementation programs in Ghana, Kenya, and Malawi have vaccinated over 2 million children, confirming feasibility and acceptable safety profiles, yet coverage gaps, logistical barriers, and interaction with seasonal malaria chemoprevention persist. Cost-effectiveness analyses support integration into existing vaccination schedules in high-burden settings, though long-term population-level impact requires ongoing surveillance. RTS, S/AS01 represents a significant advance in malaria control but requires complementary interventions and next-generation vaccine development to achieve elimination targets in endemic regions.

Keywords: RTS, S/AS01, Malaria vaccine, Circumsporozoite protein, Pediatric immunization, Sub-Saharan Africa.

INTRODUCTION

Malaria remains one of the most devastating infectious diseases globally, with an estimated 241 million cases and 627,000 deaths reported in 2020, predominantly among children under five years of age in sub-Saharan Africa [1, 2]. The burden is particularly severe in high-transmission regions where *Plasmodium falciparum* accounts for more than 95% of infections, contributing to substantial pediatric mortality, neurodevelopmental impairment, and economic losses [3]. Despite significant progress through insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies, transmission remains stubbornly persistent in endemic areas, and emerging drug and insecticide resistance threatens existing control measures. The development of an effective malaria vaccine has been a global health priority for decades, yet the complex lifecycle of *Plasmodium* parasites, antigenic variability, and incomplete understanding of protective immunity have hindered vaccine development.

The RTS, S/AS01 vaccine (Mosquirix™), developed by GlaxoSmithKline in partnership with PATH Malaria Vaccine Initiative, represents a landmark achievement as the first malaria vaccine to receive regulatory approval and

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

WHO recommendation for widespread use in children living in moderate-to-high transmission settings [4]. Following extensive Phase III trials and pilot implementation programs in Ghana, Kenya, and Malawi initiated in 2019, RTS, S/AS01 has been deployed to over 30 million children, generating critical real-world evidence on safety, effectiveness, and programmatic feasibility [5]. The objective of this review is to critically synthesize current evidence on the molecular mechanisms, clinical efficacy, immunological responses, implementation challenges, and future directions of RTS, S/AS01 vaccination in high-transmission sub-Saharan African pediatric populations.

METHODOLOGY

A comprehensive literature search was conducted in PubMed/Medline, Embase, and Web of Science databases covering January 2015 to September 2024. Search terms included "RTS, S," "AS01," "malaria vaccine," "circumsporozoite protein," "Plasmodium falciparum," "pediatric," "sub-Saharan Africa," "efficacy," "immunogenicity," "implementation," and "cost-effectiveness," combined using Boolean operators. Inclusion criteria encompassed randomized controlled trials, observational studies, systematic reviews, meta-analyses, immunological analyses, and implementation reports focused on RTS, S/AS01 in pediatric populations. Exclusion criteria included non-English publications, case reports, editorials without primary data, and studies exclusively in adult populations or non-African settings. Additional sources included WHO technical reports, Gavi policy briefs, and regulatory documents. Evidence synthesis prioritized high-quality studies, with critical appraisal of methodology, sample size, and potential bias. Where quantitative data permitted, effect sizes, confidence intervals, and heterogeneity across studies were summarized. This narrative review synthesizes mechanistic, clinical, and programmatic evidence to provide a comprehensive assessment of RTS, S/AS01 in high-transmission African pediatric populations.

MOLECULAR AND BIOCHEMICAL BASIS OF RTS, S/AS01 VACCINE

Circumsporozoite Protein Structure and Function

The RTS, S/AS01 vaccine targets the circumsporozoite protein (CSP), the most abundant surface antigen expressed on *Plasmodium falciparum* sporozoites [6]. CSP is a 412-amino acid glycoprotein consisting of an N-terminal domain, a central repeat region containing multiple NANP (asparagine-alanine-asparagine-proline) tetrapeptide repeats, and a C-terminal domain harboring the thrombospondin repeat (TSR) domain [7]. The central NANP repeats, typically 37–44 copies in *P. falciparum*, serve as the primary immunogenic target and mediate initial hepatocyte recognition through heparan sulfate proteoglycan binding. The TSR domain facilitates high-affinity binding to CD81 receptors on hepatocytes, enabling sporozoite invasion and establishment of pre-erythrocytic infection. CSP also possesses immune evasion properties, including suppression of interleukin-12 production and dendritic cell maturation, contributing to the parasite's ability to evade innate immune responses during the liver stage.

Vaccine Composition and Adjuvant System

RTS, S consists of a recombinant fusion protein comprising the central NANP repeat region and the C-terminal domain of CSP fused to the hepatitis B surface antigen (HBsAg) [8]. The construct forms virus-like particles presenting approximately 200 copies of the hybrid protein alongside unfused HBsAg in a 1:4 molar ratio, generating highly immunogenic particulate structures that enhance antigen presentation. The vaccine is formulated with AS01, a liposome-based adjuvant system containing two immunostimulants: 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a Toll-like receptor 4 agonist, and QS-21, a saponin fraction from *Quillaja saponaria* that enhances both humoral and cellular immunity. AS01 induces rapid innate immune activation, characterized by local cytokine production (interferon-gamma, interleukin-2), dendritic cell activation, and trafficking to draining lymph nodes, thereby promoting robust CD4+ T-cell responses and high-titer antibody production [9]. The liposomal formulation enhances antigen uptake by antigen-presenting cells and provides depot effects, sustaining immune stimulation.

Mechanisms of Protective Immunity

RTS, S/AS01-induced protection operates through multiple immunological mechanisms. High-titer anti-CSP antibodies, particularly those targeting the NANP repeat region, neutralize sporozoites in the skin and circulation, preventing hepatocyte invasion [10, 11]. Antibody-mediated opsonization facilitates sporozoite clearance by phagocytic cells, while antibody-dependent cellular cytotoxicity may eliminate infected hepatocytes during early liver-stage development. CD4+ T-helper responses, predominantly Th1-polarized, provide critical support for antibody class switching and generation of long-lived plasma cells. However, cytotoxic CD8+ T-cell responses, which are crucial for eliminating intrahepatic parasites in experimental models, are poorly induced by RTS, S/AS01, representing a major immunological limitation. The incomplete protection observed in clinical trials likely reflects this narrow immune focus on antibody-mediated sporozoite neutralization without robust cellular immunity against liver-stage parasites.

CLINICAL EFFICACY AND IMMUNOLOGICAL RESPONSES IN PEDIATRIC POPULATIONS

Phase III Trial Outcomes in High-Transmission Settings

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The pivotal Phase III trial, conducted across 11 sites in seven sub-Saharan African countries (2009–2014), enrolled 15,459 children in two age cohorts: 6–12 weeks and 5–17 months [12]. In the older cohort (5–17 months), receiving four doses (0, 1, 2, and 20 months), vaccine efficacy against clinical malaria over 48 months was 36.3% (95% CI: 31.8–40.5%), while efficacy against severe malaria was 32.2% (95% CI: 13.7–46.9%). In the younger cohort (6–12 weeks), co-administered with routine Expanded Programme on Immunization vaccines, efficacy was substantially lower: 25.9% (95% CI: 19.9–31.5%) against clinical malaria and 26.0% (95% CI: −7.4 to 48.6%) against severe malaria. Notably, vaccine efficacy waned significantly over time, declining from approximately 50% in the first year to below 20% by year four, underscoring the importance of the fourth booster dose at 20 months. Among children receiving only three doses without the booster, efficacy against clinical malaria fell to 28.3%, compared to 36.3% with the full four-dose regimen. Geographic heterogeneity in efficacy was evident, with lower protection observed in areas of highest transmission intensity, likely reflecting overwhelming parasite exposure and rapid immune decay.

Immunogenicity and Correlates of Protection

Anti-CSP antibody titers peak one month after the third dose, reaching geometric mean concentrations of 116.9 to 225.3EU/mL in the 5–17 month cohort, compared to baseline values near the limit of detection [13]. However, titers decline exponentially, with half-lives of approximately 1–2 years, necessitating booster immunization. Higher anti-CSP antibody levels correlate moderately with reduced infection risk (hazard ratio 0.89 per log10 increase in titer), though this relationship is imperfect, indicating that antibody quantity alone does not fully predict protection. Antibody avidity, subclass distribution (IgG1 and IgG3 dominance), and functional activity in sporozoite invasion inhibition assays provide additional correlates. CD4+ T-cell responses, measured by interferon-gamma production following *in vitro* stimulation with CSP peptides, are detectable in high quantities in vaccinees but show limited correlation with clinical protection [14]. Intriguingly, children with pre-existing malaria exposure exhibit more rapid antibody waning, potentially due to antigen-driven immune dysregulation or antibody consumption, complicating the interpretation of vaccine performance in endemic populations.

Safety Profile and Adverse Events

RTS, S/AS01 demonstrates an acceptable safety profile comparable to other pediatric vaccines [15]. Common local reactions include injection-site pain (40–50%), swelling (20–30%), and erythema, while systemic reactions such as fever (30–40%) and irritability are transient and resolve within 48 hours. Serious adverse events occur at rates similar to control groups, with no evidence of vaccine-associated increased mortality. However, post-hoc analysis of Phase III data revealed a small but statistically significant increase in meningitis cases (22 in the RTS, S group versus 11 in controls; incidence rate ratio 1.39, 95% CI: 0.67–2.91), though subsequent investigation found no biological plausibility or causal mechanism [16]. Female children receiving four doses showed a non-significant trend toward increased all-cause mortality (hazard ratio 1.24, 95% CI: 0.92–1.67), prompting intensive scrutiny but ultimately attributed to chance given multiple comparisons. The AS01 adjuvant has been associated with enhanced reactogenicity compared to aluminum-based adjuvants, though benefits in immunogenicity outweigh these concerns. Long-term safety surveillance in pilot implementation programs has confirmed these findings, with no new safety signals emerging among over 2 million vaccinated children.

IMPLEMENTATION EXPERIENCE IN PILOT PROGRAMS

Programmatic Design and Delivery Platforms

Following the WHO recommendation in 2021, three countries, Ghana, Kenya, and Malawi, launched coordinated pilot implementation programs to evaluate RTS, S/AS01 feasibility, coverage, and impact under real-world conditions [12]. The vaccine is delivered through routine Expanded Programme on Immunization platforms, with doses administered at approximately 6, 7, 9, and 24 months of age, aligned with existing childhood vaccination schedules. This integration strategy leverages established cold-chain infrastructure, health worker training systems, and community outreach mechanisms, minimizing incremental programmatic costs. Coverage targets of ≥80% for the first dose and ≥60% for the fourth dose were established, though actual coverage varies substantially by region, ranging from 60% to 95% for dose one and 45% to 75% for dose four, reflecting disparities in health system access, vaccine hesitancy, and geographic barriers.

Real-World Effectiveness and Impact

Preliminary impact data from pilot programs demonstrate significant reductions in malaria-related hospitalizations and mortality. In Ghana, regions with high vaccine coverage experienced a 30% reduction in severe malaria admissions among age-eligible children compared to pre-implementation periods [17]. Kenyan data reveal similar trends, with adjusted vaccine effectiveness of 38% (95% CI: 28–47%) against hospitalized malaria, consistent with Phase III efficacy estimates [18]. Critically, no evidence of mortality displacement to unvaccinated age groups or increased severe disease in vaccinated children who experience breakthrough infections has been observed, addressing theoretical concerns about immune interference. However, effectiveness appears lower in areas practicing seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine, likely due to

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

overlapping protection and difficulty isolating vaccine-specific effects. Ongoing pharmacovigilance has confirmed the Phase III safety profile, with adverse event rates within expected ranges.

Operational Challenges and Barriers to Coverage

Implementation experience has illuminated multiple operational challenges. Cold-chain capacity constraints limit vaccine storage and distribution in remote areas, requiring targeted infrastructure investments. Health worker training and supervision demands are substantial, particularly for accurate dose timing and adverse event recognition [19]. Vaccine hesitancy, fueled by misinformation regarding the modest efficacy (perceived as "too low" by some communities) and unfamiliarity with malaria vaccines, necessitates intensive community engagement and education campaigns. Four-dose schedule completion remains problematic, with drop-out rates between doses three and four averaging 20–30%, driven by missed opportunities, population mobility, and competing priorities. Integration with SMC, which targets children 3–59 months during high-transmission seasons, creates scheduling conflicts and operational complexity, requiring coordinated planning between vertical programs. Supply chain management, including timely procurement and forecasting, has encountered delays, highlighting the need for strengthened logistics systems.

COST-EFFECTIVENESS AND POLICY CONSIDERATIONS

Economic Evaluations and Resource Allocation

Multiple cost-effectiveness analyses support the RTS, S/AS01 introduction in high-transmission settings. Using disability-adjusted life years (DALYs) as the outcome metric, studies estimate incremental cost-effectiveness ratios of $30–$150 per DALY averted when the vaccine is added to existing malaria control interventions, well below the WHO cost-effectiveness threshold (GDP per capita) for most sub-Saharan African countries [20]. At an anticipated supply price of $5–$9 per dose, total programmatic costs (including delivery, cold chain, and training) approximate $20–$40 per fully vaccinated child. Budget impact analyses suggest that integrating RTS, S/AS01 into national immunization programs requires annual investments of $15–$50 million per country, depending on birth cohort size and coverage targets, representing 2–5% increases in existing immunization budgets. Favorable cost-effectiveness is contingent on sustained efficacy, high coverage (≥70% for four doses), and relatively stable malaria transmission; in very-low-transmission or epidemic-prone settings, cost-effectiveness diminishes substantially.

Interaction with Existing Malaria Control Tools

RTS,S/AS01 is designed as a complementary intervention, not a replacement for proven strategies such as insecticide-treated bed nets, indoor residual spraying, and prompt case management with artemisinin-based combination therapies [21]. Modeling studies indicate additive benefits when the vaccine is layered onto comprehensive vector control and treatment programs, potentially averting an additional 20–30% of cases beyond existing tools. However, concerns regarding potential negative interactions, particularly with SMC, have emerged. While theoretical immune interference has not materialized, operational challenges in coordinating SMC cycles with vaccine schedules complicate simultaneous implementation. Emerging evidence suggests that combining RTS,S/AS01 with intermittent preventive treatment in infants or seasonal chemoprevention yields synergistic protection, though optimal scheduling and drug selection require further investigation [22–24]. Vector control remains paramount, as reduced mosquito exposure amplifies vaccine-induced immunity by lowering antigen exposure and delaying immune waning.

Equity and Access Considerations

Equity in vaccine access represents a critical policy consideration. Children in the most remote, underserved areas where malaria burden is highest face the greatest barriers to achieving four-dose coverage, risking exacerbation of health disparities. Targeted strategies, including mobile vaccination teams, community-based delivery, and integration with vitamin A supplementation or deworming campaigns, may enhance reach. Vaccine supply constraints pose additional equity challenges; global manufacturing capacity currently limits availability to pilot countries, and scale-up to all endemic countries will require substantial production expansion. Gavi, the Vaccine Alliance, has committed $155 million to support RTS,S/AS01 introduction in eligible countries, though sustained financing beyond initial implementation phases remains uncertain [25, 26]. Transparent prioritization frameworks, balancing epidemiological burden, health system readiness, and equity principles, are essential to guide allocation decisions.

FUTURE DIRECTIONS AND RESEARCH GAPS

Next-Generation Malaria Vaccines

RTS, S/AS01's modest efficacy and waning immunity underscore the need for improved vaccines. R21/Matrix-M, a second-generation CSP-targeting vaccine developed by Oxford University, has demonstrated 75–77% efficacy over 12 months in Phase IIb trials in Burkina Faso, substantially exceeding RTS,S/AS01 performance [27]. R21 employs a higher antigen dose and a different adjuvant (Matrix-M, a saponin-based formulation), potentially explaining superior immunogenicity. Phase III trials are underway, and WHO prequalification is anticipated in 2024–2025. Beyond pre-erythrocytic vaccines, blood-stage candidates targeting merozoite surface proteins (e.g., RH5-based

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

vaccines) and transmission-blocking vaccines targeting sexual-stage antigens (e.g., Pfs25, Pfs230) are in various development stages. Multi-stage vaccines, combining pre-erythrocytic and blood-stage antigens, may provide broader protection, though formulation complexity and regulatory pathways pose challenges. Additionally, whole-sporozoite vaccines (irradiated or genetically attenuated) induce potent CD8+ T-cell responses but face manufacturing and cold-chain hurdles.

Genomic Surveillance and Antigenic Diversity

Plasmodium falciparum exhibits substantial genetic diversity, particularly within the CSP NANP repeat region, where repeat number varies from 33 to 37 copies, and non-NANP insertions (NVDP, NPDP) occur [28, 29]. Although RTS, S/AS01 targets the conserved NANP motif, emerging evidence suggests that parasites with variant repeat structures may escape vaccine-induced immunity, contributing to breakthrough infections. Genomic surveillance of circulating parasite populations in vaccine-implementation areas is critical to monitor selective pressure and potential immune evasion. Fortunately, large-scale sequencing studies to date have not identified consistent vaccine-driven selection, though continued vigilance is warranted. Future vaccines incorporating broader epitope coverage, including C-terminal and junctional regions, may mitigate escape risks.

Integration with Broader Malaria Elimination Strategies

RTS,S/AS01 represents one component of a comprehensive malaria elimination toolkit. Mathematical modeling suggests that achieving elimination in high-transmission settings requires sustained interventions achieving 90% reductions in transmission, necessitating maximal coverage of vector control, case management, chemoprevention, and vaccination [30]. Vaccine introduction must be accompanied by strengthened surveillance systems to detect and respond to outbreaks, parasite drug resistance monitoring, and entomological surveillance for insecticide resistance. Additionally, socio-economic development, improved housing, and environmental management contribute to long-term transmission reduction. The malaria research community increasingly emphasizes precision public health approaches, tailoring intervention packages to local epidemiology, transmission intensity, and health system capacity, rather than one-size-fits-all strategies.

Unresolved Questions and Research Priorities

Several critical questions remain. The duration of protection beyond four years is poorly characterized, and the need for additional booster doses in adolescence or adulthood is unclear. Optimal vaccine schedules, including alternative dosing intervals and fractional dosing to extend supply, require investigation. The biological basis for reduced efficacy in infants receiving RTS,S/AS01 alongside routine vaccines deserves mechanistic study, as does the potential for immune interference with other childhood vaccines [31]. The impact of maternal antibodies on infant vaccine responses remains incompletely understood. Finally, the role of genetic factors, including human leukocyte antigen polymorphisms and innate immune gene variants, in modulating vaccine efficacy warrants exploration, potentially enabling personalized vaccination strategies.

CONCLUSION

RTS, S/AS01 represents a transformative advance in malaria control, offering the first licensed vaccine against a parasitic disease and a critical new tool for protecting vulnerable pediatric populations in sub-Saharan Africa. Despite modest efficacy of approximately 36% against clinical malaria and 32% against severe disease, the vaccine delivers meaningful public health impact when integrated into comprehensive malaria control programs, averting substantial morbidity and mortality in high-transmission settings. Pilot implementation programs in Ghana, Kenya, and Malawi have demonstrated programmatic feasibility, acceptable safety, and real-world effectiveness consistent with trial data, supporting WHO's recommendation for widespread deployment. However, significant challenges persist, including waning immunity necessitating four-dose schedules, operational barriers to achieving high coverage, interaction complexities with seasonal malaria chemoprevention, and equity concerns in reaching the most vulnerable populations. The vaccine's mechanism targeting the circumsporozoite protein to induce neutralizing antibodies provides incomplete protection due to limited cellular immunity and antigenic diversity. Moving forward, RTS, S/AS01 should be viewed as a foundational intervention requiring complementary strategies, including next-generation vaccines with higher efficacy, sustained investment in vector control and case management, and genomic surveillance to monitor immune evasion. The lessons learned from RTS, S/AS01 development and implementation provide invaluable insights for accelerating malaria vaccine innovation and achieving the ambitious goal of malaria elimination in endemic regions. National malaria control programs in high-transmission sub-Saharan African countries should integrate RTS, S/AS01 into routine immunization schedules alongside sustained investment in vector control, case management, and next-generation vaccine development to maximize pediatric protection and advance toward malaria elimination.

REFERENCES

1. Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2. Erisa, K., Raphael, I., Okechukwu Paul-Chima, U., Esther Ugo, A.: Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. 1, 101–108 (2023)
3. Ogbonnia Egwu, C., Aloke, C., Chukwu, J., Agwu, A., Tsamesidis, I., E Offor, C., Ajuka Obasi, N., Aja, P.M.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
4. Laurens, M.B.: RTS,S/AS01 vaccine (Mosquirix™): an overview. Hum Vaccin Immunother. 16, 480 (2019). https://doi.org/10.1080/21645515.2019.1669415
5. Asante, K.P., Mathanga, D.P., Milligan, P., Akech, S. et al.: Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. The Lancet. 403, 1660–1670 (2024). https://doi.org/10.1016/S0140-6736(24)00004-7
6. Ainebyoona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.C., Uti, D.E., Alum, B.N, Echegu, D.A. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication (2025). Ethiopian Journal of Health Sciences, 2025; 35(3): 205-217. doi: 10.4314/ejhs.v35i3.9. PMID: 40717722; PMCID: PMC12287706.
7. Plassmeyer, M.L., Reiter, K., Shimp, R.L., Kotova, S., Smith, P.D., Hurt, D.E., House, B., Zou, X., Zhang, Y., Hickman, M., Uchime, O., Herrera, R., Nguyen, V., Glen, J., Lebowitz, J., Jin, A.J., Miller, L.H., MacDonald, N.J., Wu, Y., Narum, D.L.: Structure of the Plasmodium falciparum Circumsporozoite Protein, a Leading Malaria Vaccine Candidate. J Biol Chem. 284, 26951 (2009). https://doi.org/10.1074/JBC.M109.013706
8. Ngulube, P.: Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update. Infect Drug Resist. 16, 2147–2157 (2023). https://doi.org/10.2147/IDR.S401247
9. Barik, A., Dey, S.: Nanotechnology-Based Vaccination for TB. Infectious Diseases-Drug Delivery Systems. 147–168 (2023). https://doi.org/10.1007/978-3-031-20521-7_7
10. Wang, L.T., Pereira, L.S., Flores-Garcia, Y., O'Connor, J., Flynn, B.J., Schön, A., Hurlburt, N.K., Dillon, M., Yang, A.S.P., Fabra-García, A., Idris, A.H., Mayer, B.T., Gerber, M.W., Gottardo, R., Mason, R.D., Cavett, N., Ballard, R.B., Kisalu, N.K., Molina-Cruz, A., Nelson, J., Vistein, R., Barillas-Mury, C., Amino, R., Baker, D., King, N.P., Sauerwein, R.W., Pancera, M., Cockburn, I.A., Zavala, F., Francica, J.R., Seder, R.A.: A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity. 53, 733 (2020). https://doi.org/10.1016/J.IMMUNI.2020.08.014
11. Mitchell, R.A.: Humoral and Cellular Immune Responses to Pre-Erythrocytic Malaria Vaccination and Impact of Epidemiological Factors. Tesis Doctorals - Facultat - Medicina i Ciències de la Salut. (2024)
12. Laurens, M.B.: RTS,S/AS01 vaccine (Mosquirix™): an overview. Hum Vaccin Immunother. 16, 480–489 (2020). https://doi.org/10.1080/21645515.2019.1669415
13. Mitchell, R.A.: Humoral and Cellular Immune Responses to Pre-Erythrocytic Malaria Vaccination and Impact of Epidemiological Factors. Tesis Doctorals - Facultat - Medicina i Ciències de la Salut. (2024)
14. Pattinson, D.J., Apte, S.H., Wibowo, N., Rivera-Hernandez, T., Groves, P.L., Middelberg, A.P.J., Doolan, D.L.: Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8+ T Cell Responses but Differ in Capacity to Induce CD4+ T Cell Responses and Antibody Responses. Front Immunol. 11, 564627 (2020). https://doi.org/10.3389/FIMMU.2020.564627/BIBTEX
15. Guerra Mendoza, Y., Garric, E., Leach, A., Lievens, M., Ofori-Anyinam, O., Pirçon, J.Y., Stegmann, J.U., Vandoolaeghe, P., Otieno, L., Otieno, W., Owusu-Agyei, S., Sacarlal, J., Masoud, N.S., Sorgho, H., Tanner, M., Tinto, H., Valea, I., Mtoro, A.T., Njuguna, P., Oneko, M., Otieno, G.A., Otieno, K., Gesase, S., Hamel, M.J., Hoffman, I., Kaali, S., Kamthunzi, P., Kremsner, P., Lanaspa, M., Lell, B., Lusingu, J., Malabeja, A., Aide, P., Akoo, P., Ansong, D., Asante, K.P., Berkley, J.A., Adjei, S., Agbenyega, T., Agnandji, S.T., Schuerman, L.: Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother. 15, 2386–2398 (2019). https://doi.org/10.1080/21645515.2019.1586040
16. Agyapong, P.D., Akite, E.J., Ansah, N.A., Ansah, P.O., Asante, K.P., Awuni, D.A., Azongo, D.K., Boahen, O., Bozonnat, M.C., Copeland, N.K., Guerra Mendoza, Y., Haine, V., Harrison, S.B.E., Kaali, S., Kaburise, M.B., Oduro, A., Oguk, E., Otieno, L., Otieno, W., Owusu-Agyei, S., Oyieko, J., Pirçon, J.Y., Praet, N., Roman, F., Schuerman, L., Sing'oei, V., Tivura, M.: Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine. Malar J. 20, 1–12 (2021). https://doi.org/10.1186/S12936-021-03670-W/FIGURES/2
17. Adjei, M.R., Amponsa-Achiano, K., Okine, R., Tweneboah, P.O., Sally, E.T., Dadzie, J.F., Osei-Sarpong, F., Adjabeng, M.J., Bawa, J.T., Bonsu, G., Antwi-Agyei, K.O., Kaburi, B.B., Owusu-Antwi, F., Juma, E., Kasolo,

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

F.C., Asiedu-Bekoe, F., Kuma-Aboagye, P.: Post introduction evaluation of the malaria vaccine implementation programme in Ghana, 2021. BMC Public Health. 23, 1–8 (2023). https://doi.org/10.1186/S12889-023-15481-6/FIGURES/5

18. Asante, K.P., Mathanga, D.P., Milligan, P., Akech, S., Oduro, A., Mwapasa, V., Moore, K.A., Kwambai, T.K., Hamel, M.J., Gyan, T., Westercamp, N., Kapito-Tembo, A., Njuguna, P., Ansong, D., Kariuki, S., Mvalo, T., Snell, P., Schellenberg, D., Welega, P., Otieno, L., Chimala, A., Afari, E.A., Bejon, P., Maleta, K., Agbenyega, T., Snow, R.W., Zulu, M., Chinkhumba, J., Samuels, A.M., Abubakari, S.W., Akumani, A., Adu-Gyasi, D., Sarfo, A., Odei-Lartey, E., Agbokey, F., Amenga-Etego, S., Gyaase, S., Buabeng, P., Awini, E., Sylverken, J., Kampim, A., Koram, K.A., Hodgson, A., Binka, F.N., Okine, R.N.A., Tweneboah, P.O., Ondiegi, B., Seda, B., Akach, D., Orwa, G., Nyang'au, I., Odunga, O., Gumba, F., Copeland, N., Khazenzi, C., Mumo, E., Musa, M., Ogero, M., English, M., Haji, A., Njoroge, J., Msuku, H., Samuel, V., Mariko, H.T., Juliano, J., Msumba, L., Mungwira, R.G., Zimba, B.E., Desai, M., Furrer, E., Aponte, J., Alonso, P., Kalu, A.A., Sillah, J.S.: Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. The Lancet. 403, 1660–1670 (2024). https://doi.org/10.1016/S0140-6736(24)00004-7
19. Sarre, S., Maben, J., Aldus, C., Schneider, J., Wharrad, H., Nicholson, C., Arthur, A.: The challenges of training, support and assessment of healthcare support workers: A qualitative study of experiences in three English acute hospitals. Int J Nurs Stud. 79, 145–153 (2018). https://doi.org/10.1016/J.IJNURSTU.2017.11.010
20. Mezieobi, K.C., Ugwu, O.P.C., Uti, D.E., Egba, S.I., Ewah, C.M. Economic burden of malaria on developing countries: A mini review. Parasite Epidemiology and Control.30 (2025), e00435. https://doi.org/10.1016/j.parepi.2025.e00435
21. Ugwu, O.P.C., Egba, S.I., Uti, D.E., Alum, B.N. Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research 11(2):16-22. (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
22. Dicko, A., Ouedraogo, J.B., Zongo, I., Sagara, I., Cairns, M., Yerbanga, R.S., Issiaka, D., Zoungrana, C., Sidibe, Y., Tapily, A., Nikièma, F., Sompougdou, F., Sanogo, K., Kaya, M., Yalcouye, H., Dicko, O.M., Diarra, M., Diarra, K., Thera, I., Haro, A., Sienou, A.A., Traore, S., Mahamar, A., Dolo, A., Kuepfer, I., Snell, P., Grant, J., Webster, J., Milligan, P., Lee, C., Ockenhouse, C., Ofori-Anyinam, O., Tinto, H., Djimde, A., Chandramohan, D., Greenwood, B.: Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 24, 75–86 (2024). https://doi.org/10.1016/S1473-3099(23)00368-7
23. Yihunie, W., Abebe, D., Kebede, B., Tegegne, B.A., Getachew, M., Aschale, Y., Belew, H., Bahiru, B.: Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults. Clin Pharmacol. 15, 21–32 (2023). https://doi.org/10.2147/CPAA.S400155
24. Alum, E. U. Phytochemicals in Malaria Treatment: Mechanisms of Action and Clinical Efficacy. KIU J. Health Sci., 4(2):71-84. (2024). https://doi.org/10.59568/KJHS-2024-4-2-06.
25. Greater support needed for health systems in high disease burden countries to ensure equitable distribution of malaria vaccine | Malaria Consortium, https://www.malariaconsortium.org/news/greater-support-needed-for-health-systems-in-high-disease-burden-countries-to-ensure-equitable-distribution-of-malaria-vaccine
26. Merle, C.S., Badiane, N.A., Affoukou, C.D., Affo, S.Y., Djogbenou, S.L., Hounto, A., Kompaore, S.C.B., Ouedraogo, I., Ateba, M.J., Njoh, A.A., Bomba, D., Tchokfe, S.N., Ali, I.M., Camara, F., Mbodj, M., Sosler, S., Rono, J., Noonan, L., Venu, M., Tanko, M.N., Gyan, T., Gyapong, M., Nante, J.E., Intchala, H.I., Camara, M.B., Cisse, G., Loua, J.E., Jalang'o, R., Milligan, P., Scott, S., Baker, K., Sande, J., Mhone, B.L., Kone, A., Coulibaly, Y., Diarra, I., Tchouatieu, A.M., Aliaprieto, M., Diallo, I.G., Abou, Y., Assan, A.N., Jibril, H., Nmep, N., Eze, N.C., Bakunawa, G.B., Shekarau, E., Nikau, J., Gordon, S., Wilskie, E.A., Bawa, J., Badiane, N.A., Sturm-Ramirez, K., Kidwang, J.P., Sene, D., Nabykaly, J.S., Abdoulaye, K.A., Diar, M.S.I., Addi, A.M., Hennig, B.J., Yahouedo, G.A., Kolley, O., Fofana, S., Atcha-Oubou, M.N., Djobo, H.L., Mbaye, R., Ousmane, S.Y., Ndiaye, J.L.A., Amadou, S.E.C., Mbaye, I.M., Sall, F.B., Fatoudiop, N., Bakhoum, L.N., Diouf, E.H.M.B., Almamy Youssouph, L.Y., Ndiaye, K., Amankwa, B., Ong, L., Oh, C., Wirngo, B., Kung, L., Hedje, J., Tuitai, L., Efe-Aluta, O., Magafu, M., Ntabangana, S., Kande, M., Okine, R., Hamel, M., Walldorf, J., Furrer, E., Kelleher, K., Lindsey, W.U., Takamiya, M., Bergstrom, C.: Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission:

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

workshop meeting report. Malar J. 22, 1–14 (2023). https://doi.org/10.1186/S12936-023-04657-5/FIGURES/3
27. Datoo, M.S., Natama, H.M., Somé, A., Bellamy, D., Traoré, O., Rouamba, T., Tahita, M.C., Ido, N.F.A., Yameogo, P., Valia, D., Millogo, A., Ouedraogo, F., Soma, R., Sawadogo, S., Sorgho, F., Derra, K., Rouamba, E., Ramos-Lopez, F., Cairns, M., Provstgaard-Morys, S., Aboagye, J., Lawrie, A., Roberts, R., Valéa, I., Sorgho, H., Williams, N., Glenn, G., Fries, L., Reimer, J., Ewer, K.J., Shaligram, U., Hill, A.V.S., Tinto, H.: Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 22, 1728–1736 (2022). https://doi.org/10.1016/S1473-3099(22)00442-X
28. Mohamed, N.S., Abdelbagi, H., Ahmed, Mohammed, A.E., Ali, Altahir, A., Abubakr, O., Siddig, M., Omer, &: EUR Research Information Portal Assessment of genetic diversity of Plasmodium falciparum circumsporozoite protein in Sudan Citation for the published version (APA). https://doi.org/10.1186/s12936-021-03971-0
29. Murugan, R., Scally, S.W., Costa, G., Mustafa, G., Thai, E., Decker, T., Bosch, A., Prieto, K., Levashina, E.A., Julien, J.P., Wardemann, H.: Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat Med. 26, 1135–1145 (2020). https://doi.org/10.1038/S41591-020-0881-9;SUBJMETA
30. The utility of mathematical modelling of serological data in assessing the impact of vaccination programmes in Kenya, https://researchonline.lshtm.ac.uk/id/eprint/4673129/
31. Nadeem, A.Y., Shehzad, A., Islam, S.U., Al-Suhaimi, E.A., Lee, Y.S.: Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy. Vaccines 2022, Vol. 10, Page 713. 10, 713 (2022). https://doi.org/10.3390/VACCINES10050713

CITE AS: Kato Jumba K. (2026). RTS, S/AS01 Malaria Vaccine Implementation in High-Transmission Sub-Saharan African Pediatric Populations: Efficacy and Challenges. Research Output Journal of Engineering and Scientific Research 5(1): 21-28. https://doi.org/10.59298/ROJESR/2026/5.12128

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.